Cost-effectiveness of once daily GLP-1 receptor agonist lixisenatide compared to bolus insulin both in combination with basal insulin for the treatment of patients with type 2 diabetes in Norway
"I definitely had struggles because, I mean, I believed it too," she says
Acetyl-L-carnitine in neuropathic pain: experimental data [PMID: 17696591] Laboratory literature summary: Acetyl-L-carnitine in neuropathic pain: experimental data
Citing various estimates, PwC pegged the current GLP-1 market at $133 billion, with the potential to climb to $150 billion by 2030
It is not a GLP-1-only agonist, but it is often discussed alongside GLP-1 medications because many of the benefits and side effects overlap
These drugs treat chronic conditions requiring ongoing management, though individual circumstances and consultation with your healthcare provider should guide discontinuation decisions